<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20240227050924&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20240227050924&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 27 Feb 2024 10:09:24 +0000</lastbuilddate>
<pubDate>Mon, 26 Feb 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Incidence, Implications, and Treatment of Patients With Severe Aortic Stenosis and Small Aortic Annulus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38408150/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 27;149(9):656-657. doi: 10.1161/CIRCULATIONAHA.123.067816. Epub 2024 Feb 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38408150/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38408150</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067816>10.1161/CIRCULATIONAHA.123.067816</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38408150</guid>
<pubDate>Mon, 26 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Howard C Herrmann</dc:creator>
<dc:creator>Nimesh D Desai</dc:creator>
<dc:date>2024-02-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Incidence, Implications, and Treatment of Patients With Severe Aortic Stenosis and Small Aortic Annulus</dc:title>
<dc:identifier>pmid:38408150</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067816</dc:identifier>
</item>
<item>
<title>Correction to: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38408149/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 27;149(9):e936. doi: 10.1161/CIR.0000000000001218. Epub 2024 Feb 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38408149/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38408149</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001218>10.1161/CIR.0000000000001218</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38408149</guid>
<pubDate>Mon, 26 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:38408149</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001218</dc:identifier>
</item>
<item>
<title>Letter by Chen et al Regarding Article, "STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38408148/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 27;149(9):725-726. doi: 10.1161/CIRCULATIONAHA.123.066568. Epub 2024 Feb 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38408148/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38408148</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066568>10.1161/CIRCULATIONAHA.123.066568</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38408148</guid>
<pubDate>Mon, 26 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Zhongxiu Chen</dc:creator>
<dc:creator>Junyan Zhang</dc:creator>
<dc:creator>Yong He</dc:creator>
<dc:date>2024-02-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Chen et al Regarding Article, "STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial"</dc:title>
<dc:identifier>pmid:38408148</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066568</dc:identifier>
</item>
<item>
<title>Response by Van de Werf et al to Letter Regarding Article, "STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38408147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 27;149(9):727-728. doi: 10.1161/CIRCULATIONAHA.123.067368. Epub 2024 Feb 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38408147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38408147</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067368>10.1161/CIRCULATIONAHA.123.067368</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38408147</guid>
<pubDate>Mon, 26 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Frans Van de Werf</dc:creator>
<dc:creator>Peter Sinnaeve</dc:creator>
<dc:creator>Robert C Welsh</dc:creator>
<dc:creator>Paul W Armstrong</dc:creator>
<dc:date>2024-02-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Van de Werf et al to Letter Regarding Article, "STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial"</dc:title>
<dc:identifier>pmid:38408147</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067368</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38408146/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 27;149(9):717-721. doi: 10.1161/CIRCULATIONAHA.124.068940. Epub 2024 Feb 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38408146/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38408146</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068940>10.1161/CIRCULATIONAHA.124.068940</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38408146</guid>
<pubDate>Mon, 26 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:38408146</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068940</dc:identifier>
</item>
<item>
<title>Outcomes After Aspirin Discontinuation Among Baseline Users in Contemporary Primary Prevention Aspirin Trials: A Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38408145/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 27;149(9):722-724. doi: 10.1161/CIRCULATIONAHA.123.065420. Epub 2024 Feb 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38408145/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38408145</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065420>10.1161/CIRCULATIONAHA.123.065420</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38408145</guid>
<pubDate>Mon, 26 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Ruth Campbell</dc:creator>
<dc:creator>Mark R Nelson</dc:creator>
<dc:creator>John J McNeill</dc:creator>
<dc:creator>John W McEvoy</dc:creator>
<dc:date>2024-02-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Outcomes After Aspirin Discontinuation Among Baseline Users in Contemporary Primary Prevention Aspirin Trials: A Meta-Analysis</dc:title>
<dc:identifier>pmid:38408145</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065420</dc:identifier>
</item>
<item>
<title>Myocarditis: Entering the Mainstream</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38408144/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 27;149(9):639-640. doi: 10.1161/CIRCULATIONAHA.123.065484. Epub 2024 Feb 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38408144/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38408144</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065484>10.1161/CIRCULATIONAHA.123.065484</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38408144</guid>
<pubDate>Mon, 26 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Leslie T Cooper</dc:creator>
<dc:date>2024-02-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Myocarditis: Entering the Mainstream</dc:title>
<dc:identifier>pmid:38408144</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065484</dc:identifier>
</item>
<item>
<title>Strengthening the Pillars of Cardiovascular Health: Psychological Health is a Crucial Component</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38408143/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 27;149(9):641-643. doi: 10.1161/CIRCULATIONAHA.123.066132. Epub 2024 Feb 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38408143/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38408143</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066132>10.1161/CIRCULATIONAHA.123.066132</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38408143</guid>
<pubDate>Mon, 26 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Allison E Gaffey</dc:creator>
<dc:creator>Bruce L Rollman</dc:creator>
<dc:creator>Matthew M Burg</dc:creator>
<dc:date>2024-02-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Strengthening the Pillars of Cardiovascular Health: Psychological Health is a Crucial Component</dc:title>
<dc:identifier>pmid:38408143</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066132</dc:identifier>
</item>
<item>
<title>RNA Therapeutics for the Cardiovascular System</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38408142/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>RNA therapeutics hold significant promise in the treatment of cardiovascular diseases. RNAs are biologically diverse and functionally specific and can be used for gain- or loss-of-function purposes. The effectiveness of mRNA-based vaccines in the recent COVID-19 pandemic has undoubtedly proven the benefits of an RNA-based approach. RNA-based therapies are becoming more common as a treatment modality for cardiovascular disease. This is most evident in hypertension where several small interfering...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 27;149(9):707-716. doi: 10.1161/CIRCULATIONAHA.123.067373. Epub 2024 Feb 26.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RNA therapeutics hold significant promise in the treatment of cardiovascular diseases. RNAs are biologically diverse and functionally specific and can be used for gain- or loss-of-function purposes. The effectiveness of mRNA-based vaccines in the recent COVID-19 pandemic has undoubtedly proven the benefits of an RNA-based approach. RNA-based therapies are becoming more common as a treatment modality for cardiovascular disease. This is most evident in hypertension where several small interfering RNA-based drugs have proven to be effective in managing high blood pressure in several clinical trials. As befits a rapidly burgeoning field, there is significant interest in other classes of RNA. Revascularization of the infarcted heart through an mRNA drug is under clinical investigation. mRNA technology may provide the platform for the expression of paracrine factors for myocardial protection and regeneration. Emergent technologies on the basis of microRNAs and gene editing are tackling complex diseases in a novel fashion. RNA-based gene editing offers hope of permanent cures for monogenic cardiovascular diseases, and long-term control of complex diseases such as essential hypertension, as well. Likewise, microRNAs are proving effective in regenerating cardiac muscle. The aim of this review is to provide an overview of the current landscape of RNA-based therapies for the treatment of cardiovascular disease. The review describes the large number of RNA molecules that exist with a discussion of the clinical development of each RNA type. In addition, the review also presents a number of avenues for future development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38408142/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38408142</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067373>10.1161/CIRCULATIONAHA.123.067373</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38408142</guid>
<pubDate>Mon, 26 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Victor J Dzau</dc:creator>
<dc:creator>Conrad P Hodgkinson</dc:creator>
<dc:date>2024-02-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>RNA Therapeutics for the Cardiovascular System</dc:title>
<dc:identifier>pmid:38408142</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067373</dc:identifier>
</item>
<item>
<title>Cardiogenic Shock in Older Adults: A Focus on Age-Associated Risks and Approach to Management: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38406869/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>Cardiogenic shock continues to portend poor outcomes, conferring short-term mortality rates of 30% to 50% despite recent scientific advances. Age is a nonmodifiable risk factor for mortality in patients with cardiogenic shock and is often considered in the decision-making process for eligibility for various therapies. Older adults have been largely excluded from analyses of therapeutic options in patients with cardiogenic shock. As a result, despite the association of advanced age with worse...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 26. doi: 10.1161/CIR.0000000000001214. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiogenic shock continues to portend poor outcomes, conferring short-term mortality rates of 30% to 50% despite recent scientific advances. Age is a nonmodifiable risk factor for mortality in patients with cardiogenic shock and is often considered in the decision-making process for eligibility for various therapies. Older adults have been largely excluded from analyses of therapeutic options in patients with cardiogenic shock. As a result, despite the association of advanced age with worse outcomes, focused strategies in the assessment and management of cardiogenic shock in this high-risk and growing population are lacking. Individual programs oftentimes develop upper age limits for various interventional strategies for their patients, including heart transplantation and durable left ventricular assist devices. However, age as a lone parameter should not be used to guide individual patient management decisions in cardiogenic shock. In the assessment of risk in older adults with cardiogenic shock, a comprehensive, interdisciplinary approach is central to developing best practices. In this American Heart Association scientific statement, we aim to summarize our contemporary understanding of the epidemiology, risk assessment, and in-hospital approach to management of cardiogenic shock, with a unique focus on older adults.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38406869/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38406869</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001214>10.1161/CIR.0000000000001214</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38406869</guid>
<pubDate>Mon, 26 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Vanessa Blumer</dc:creator>
<dc:creator>Manreet K Kanwar</dc:creator>
<dc:creator>Christopher F Barnett</dc:creator>
<dc:creator>Jennifer A Cowger</dc:creator>
<dc:creator>Abdulla A Damluji</dc:creator>
<dc:creator>Maryjane Farr</dc:creator>
<dc:creator>Sarah J Goodlin</dc:creator>
<dc:creator>Jason N Katz</dc:creator>
<dc:creator>Colleen K McIlvennan</dc:creator>
<dc:creator>Shashank S Sinha</dc:creator>
<dc:creator>Tracy Y Wang</dc:creator>
<dc:creator>American Heart Association Cardiovascular Disease in Older Populations Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Council on Cardiovascular Surgery and Anesthesia</dc:creator>
<dc:date>2024-02-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiogenic Shock in Older Adults: A Focus on Age-Associated Risks and Approach to Management: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38406869</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001214</dc:identifier>
</item>
<item>
<title>Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38406848/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Routine PPA after primary percutaneous coronary intervention was safe but did not reduce 30-day ischemic events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 26. doi: 10.1161/CIRCULATIONAHA.123.067079. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Postprocedural anticoagulation (PPA) is frequently administered after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction, although no conclusive data support this practice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The RIGHT trial (Comparison of Anticoagulation Prolongation vs no Anticoagulation in STEMI Patients After Primary PCI) was an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled, superiority trial conducted at 53 centers in China. Patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention were randomly assigned by center to receive low-dose PPA or matching placebo for at least 48 hours. Before trial initiation, each center selected 1 of 3 PPA regimens (40 mg of enoxaparin once daily subcutaneously; 10 U·kg·h of unfractionated heparin intravenously, adjusted to maintain activated clotting time between 150 and 220 seconds; or 0.2 mg·kg·h of bivalirudin intravenously). The primary efficacy objective was to demonstrate superiority of PPA to reduce the primary efficacy end point of all-cause death, nonfatal myocardial infarction, nonfatal stroke, stent thrombosis (definite), or urgent revascularization (any vessel) within 30 days. The key secondary objective was to evaluate the effect of each specific anticoagulation regimen (enoxaparin, unfractionated heparin, or bivalirudin) on the primary efficacy end point. The primary safety end point was Bleeding Academic Research Consortium 3 to 5 bleeding at 30 days.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between January 10, 2019, and September 18, 2021, a total of 2989 patients were randomized. The primary efficacy end point occurred in 37 patients (2.5%) in both the PPA and placebo groups (hazard ratio, 1.00 [95% CI, 0.63 to 1.57]). The incidence of Bleeding Academic Research Consortium 3 or 5 bleeding did not differ between the PPA and placebo groups (8 [0.5%] vs 11 [0.7%] patients; hazard ratio, 0.74 [95% CI, 0.30 to 1.83]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Routine PPA after primary percutaneous coronary intervention was safe but did not reduce 30-day ischemic events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03664180.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38406848/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38406848</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067079>10.1161/CIRCULATIONAHA.123.067079</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38406848</guid>
<pubDate>Mon, 26 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Yan Yan</dc:creator>
<dc:creator>Jincheng Guo</dc:creator>
<dc:creator>Xiao Wang</dc:creator>
<dc:creator>Guozhong Wang</dc:creator>
<dc:creator>Zeyuan Fan</dc:creator>
<dc:creator>Delu Yin</dc:creator>
<dc:creator>Zhifang Wang</dc:creator>
<dc:creator>Fuchun Zhang</dc:creator>
<dc:creator>Changming Tian</dc:creator>
<dc:creator>Wei Gong</dc:creator>
<dc:creator>Jiamin Liu</dc:creator>
<dc:creator>Jiapeng Lu</dc:creator>
<dc:creator>Yongjun Li</dc:creator>
<dc:creator>Changsheng Ma</dc:creator>
<dc:creator>Eric Vicaut</dc:creator>
<dc:creator>Gilles Montalescot</dc:creator>
<dc:creator>Shaoping Nie</dc:creator>
<dc:creator>RIGHT Investigators</dc:creator>
<dc:date>2024-02-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial</dc:title>
<dc:identifier>pmid:38406848</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067079</dc:identifier>
</item>
<item>
<title>Learning attentional templates for value-based decision-making</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38401541/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>Attention filters sensory inputs to enhance task-relevant information. It is guided by an "attentional template" that represents the stimulus features that are currently relevant. To understand how the brain learns and uses templates, we trained monkeys to perform a visual search task that required them to repeatedly learn new attentional templates. Neural recordings found that templates were represented across the prefrontal and parietal cortex in a structured manner, such that perceptually...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 21:S0092-8674(24)00110-7. doi: 10.1016/j.cell.2024.01.041. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Attention filters sensory inputs to enhance task-relevant information. It is guided by an "attentional template" that represents the stimulus features that are currently relevant. To understand how the brain learns and uses templates, we trained monkeys to perform a visual search task that required them to repeatedly learn new attentional templates. Neural recordings found that templates were represented across the prefrontal and parietal cortex in a structured manner, such that perceptually neighboring templates had similar neural representations. When the task changed, a new attentional template was learned by incrementally shifting the template toward rewarded features. Finally, we found that attentional templates transformed stimulus features into a common value representation that allowed the same decision-making mechanisms to deploy attention, regardless of the identity of the template. Altogether, our results provide insight into the neural mechanisms by which the brain learns to control attention and how attention can be flexibly deployed across tasks.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38401541/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38401541</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.041>10.1016/j.cell.2024.01.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38401541</guid>
<pubDate>Sat, 24 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Caroline I Jahn</dc:creator>
<dc:creator>Nikola T Markov</dc:creator>
<dc:creator>Britney Morea</dc:creator>
<dc:creator>Nathaniel D Daw</dc:creator>
<dc:creator>R Becket Ebitz</dc:creator>
<dc:creator>Timothy J Buschman</dc:creator>
<dc:date>2024-02-24</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Learning attentional templates for value-based decision-making</dc:title>
<dc:identifier>pmid:38401541</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.041</dc:identifier>
</item>
<item>
<title>Targeting NPM1 Epigenetically Promotes Postinfarction Cardiac Repair by Reprogramming Reparative Macrophage Metabolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38390737/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings uncover the key role of epigenetic factor NPM1 in impeding postinfarction cardiac repair by remodeling metabolism pattern and impairing the reparative function of cardiac macrophages. NPM1 may serve as a promising prognostic biomarker and a valuable therapeutic target for heart failure after MI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 23. doi: 10.1161/CIRCULATIONAHA.123.065506. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Reparative macrophages play a crucial role in limiting excessive fibrosis and promoting cardiac repair after myocardial infarction (MI), highlighting the significance of enhancing their reparative phenotype for wound healing. Metabolic adaptation orchestrates the phenotypic transition of macrophages; however, the precise mechanisms governing metabolic reprogramming of cardiac reparative macrophages remain poorly understood. In this study, we investigated the role of NPM1 (nucleophosmin 1) in the metabolic and phenotypic shift of cardiac macrophages in the context of MI and explored the therapeutic effect of targeting NPM1 for ischemic tissue repair.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Peripheral blood mononuclear cells were obtained from healthy individuals and patients with MI to explore NPM1 expression and its correlation with prognostic indicators. Through RNA sequencing, metabolite profiling, histology, and phenotype analyses, we investigated the role of NPM1 in postinfarct cardiac repair using macrophage-specific NPM1 knockout mice. Epigenetic experiments were conducted to study the mechanisms underlying metabolic reprogramming and phenotype transition of NPM1-deficient cardiac macrophages. The therapeutic efficacy of antisense oligonucleotide and inhibitor targeting NPM1 was then assessed in wild-type mice with MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: NPM1 expression was upregulated in the peripheral blood mononuclear cells from patients with MI that closely correlated with adverse prognostic indicators of MI. Macrophage-specific NPM1 deletion reduced infarct size, promoted angiogenesis, and suppressed tissue fibrosis, in turn improving cardiac function and protecting against adverse cardiac remodeling after MI. Furthermore, NPM1 deficiency boosted the reparative function of cardiac macrophages by shifting macrophage metabolism from the inflammatory glycolytic system to oxygen-driven mitochondrial energy production., The oligomeric NPM1 mechanistically recruited histone demethylase KDM5b to the promoter of <i>Tsc1</i> (<i>TSC complex subunit 1</i>), the mTOR (mechanistic target of rapamycin kinase) complex inhibitor, reduced histone H3K4me3 modification, and inhibited TSC1 expression, which then facilitated mTOR-related inflammatory glycolysis and antagonized the reparative function of cardiac macrophages. The in vivo administration of antisense oligonucleotide targeting NPM1 or oligomerization inhibitor NSC348884 substantially ameliorated tissue injury and enhanced cardiac recovery in mice after MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings uncover the key role of epigenetic factor NPM1 in impeding postinfarction cardiac repair by remodeling metabolism pattern and impairing the reparative function of cardiac macrophages. NPM1 may serve as a promising prognostic biomarker and a valuable therapeutic target for heart failure after MI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38390737/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38390737</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065506>10.1161/CIRCULATIONAHA.123.065506</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38390737</guid>
<pubDate>Fri, 23 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Sheng Zhang</dc:creator>
<dc:creator>Yunkai Zhang</dc:creator>
<dc:creator>Xuewen Duan</dc:creator>
<dc:creator>Bo Wang</dc:creator>
<dc:creator>Zhenzhen Zhan</dc:creator>
<dc:date>2024-02-23</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Targeting NPM1 Epigenetically Promotes Postinfarction Cardiac Repair by Reprogramming Reparative Macrophage Metabolism</dc:title>
<dc:identifier>pmid:38390737</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065506</dc:identifier>
</item>
<item>
<title>Pulmonary vascular compliance predicts response to VAD support</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38388962/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Feb 22. doi: 10.1038/s41569-024-01002-4. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38388962/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38388962</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01002-4>10.1038/s41569-024-01002-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38388962</guid>
<pubDate>Fri, 23 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-02-23</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Pulmonary vascular compliance predicts response to VAD support</dc:title>
<dc:identifier>pmid:38388962</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01002-4</dc:identifier>
</item>
<item>
<title>A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38387457/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>CRISPR technologies have begun to revolutionize T cell therapies; however, conventional CRISPR-Cas9 genome-editing tools are limited in their safety, efficacy, and scope. To address these challenges, we developed multiplexed effector guide arrays (MEGA), a platform for programmable and scalable regulation of the T cell transcriptome using the RNA-guided, RNA-targeting activity of CRISPR-Cas13d. MEGA enables quantitative, reversible, and massively multiplexed gene knockdown in primary human T...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 14:S0092-8674(24)00102-8. doi: 10.1016/j.cell.2024.01.035. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CRISPR technologies have begun to revolutionize T cell therapies; however, conventional CRISPR-Cas9 genome-editing tools are limited in their safety, efficacy, and scope. To address these challenges, we developed multiplexed effector guide arrays (MEGA), a platform for programmable and scalable regulation of the T cell transcriptome using the RNA-guided, RNA-targeting activity of CRISPR-Cas13d. MEGA enables quantitative, reversible, and massively multiplexed gene knockdown in primary human T cells without targeting or cutting genomic DNA. Applying MEGA to a model of CAR T cell exhaustion, we robustly suppressed inhibitory receptor upregulation and uncovered paired regulators of T cell function through combinatorial CRISPR screening. We additionally implemented druggable regulation of MEGA to control CAR activation in a receptor-independent manner. Lastly, MEGA enabled multiplexed disruption of immunoregulatory metabolic pathways to enhance CAR T cell fitness and anti-tumor activity in vitro and in vivo. MEGA offers a versatile synthetic toolkit for applications in cancer immunotherapy and beyond.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38387457/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38387457</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.035>10.1016/j.cell.2024.01.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38387457</guid>
<pubDate>Thu, 22 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Victor Tieu</dc:creator>
<dc:creator>Elena Sotillo</dc:creator>
<dc:creator>Jeremy R Bjelajac</dc:creator>
<dc:creator>Crystal Chen</dc:creator>
<dc:creator>Meena Malipatlolla</dc:creator>
<dc:creator>Justin A Guerrero</dc:creator>
<dc:creator>Peng Xu</dc:creator>
<dc:creator>Patrick J Quinn</dc:creator>
<dc:creator>Chris Fisher</dc:creator>
<dc:creator>Dorota Klysz</dc:creator>
<dc:creator>Crystal L Mackall</dc:creator>
<dc:creator>Lei S Qi</dc:creator>
<dc:date>2024-02-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells</dc:title>
<dc:identifier>pmid:38387457</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.035</dc:identifier>
</item>
<item>
<title>A Novel CMR-ECGI Lens Exposes the Electrophysiological Substrate in Subclinical HCM: A Glimmering Future Preview</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38385930/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13:S0735-1097(24)00161-X. doi: 10.1016/j.jacc.2024.01.017. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38385930/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38385930</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.017>10.1016/j.jacc.2024.01.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38385930</guid>
<pubDate>Thu, 22 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Babken Asatryan</dc:creator>
<dc:creator>Steven A Muller</dc:creator>
<dc:date>2024-02-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Novel CMR-ECGI Lens Exposes the Electrophysiological Substrate in Subclinical HCM: A Glimmering Future Preview</dc:title>
<dc:identifier>pmid:38385930</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.017</dc:identifier>
</item>
<item>
<title>Electrophysiological Characterization of Subclinical and Overt Hypertrophic Cardiomyopathy by Magnetic Resonance Imaging-Guided Electrocardiography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38385929/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the absence of LVH or 12-lead ECG abnormalities, HCM sarcomere gene mutation carriers express an aberrant EP phenotype detected by ECGI. In overt HCM, abnormalities occur more severely with adverse structural change and positive genetic status.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13:S0735-1097(24)00052-4. doi: 10.1016/j.jacc.2024.01.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Ventricular arrhythmia in hypertrophic cardiomyopathy (HCM) relates to adverse structural change and genetic status. Cardiovascular magnetic resonance (CMR)-guided electrocardiographic imaging (ECGI) noninvasively maps cardiac structural and electrophysiological (EP) properties.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to establish whether in subclinical HCM (genotype [G]+ left ventricular hypertrophy [LVH]-), ECGI detects early EP abnormality, and in overt HCM, whether the EP substrate relates to genetic status (G+/G-LVH+) and structural phenotype.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a prospective 211-participant CMR-ECGI multicenter study of 70 G+LVH-, 104 LVH+ (51 G+/53 G-), and 37 healthy volunteers (HVs). Local activation time (AT), corrected repolarization time, corrected activation-recovery interval, spatial gradients (G<sub>AT</sub>/G<sub>RTc</sub>), and signal fractionation were derived from 1,000 epicardial sites per participant. Maximal wall thickness and scar burden were derived from CMR. A support vector machine was built to discriminate G+LVH- from HV and low-risk HCM from those with intermediate/high-risk score or nonsustained ventricular tachycardia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with HV, subclinical HCM showed mean AT prolongation (P = 0.008) even with normal 12-lead electrocardiograms (ECGs) (P = 0.009), and repolarization was more spatially heterogenous (G<sub>RTc</sub>: P = 0.005) (23% had normal ECGs). Corrected activation-recovery interval was prolonged in overt vs subclinical HCM (P &lt; 0.001). Mean AT was associated with maximal wall thickness; spatial conduction heterogeneity (G<sub>AT</sub>) and fractionation were associated with scar (all P &lt; 0.05), and G+LVH+ had more fractionation than G-LVH+ (P = 0.002). The support vector machine discriminated subclinical HCM from HV (10-fold cross-validation accuracy 80% [95% CI: 73%-85%]) and identified patients at higher risk of sudden cardiac death (accuracy 82% [95% CI: 78%-86%]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the absence of LVH or 12-lead ECG abnormalities, HCM sarcomere gene mutation carriers express an aberrant EP phenotype detected by ECGI. In overt HCM, abnormalities occur more severely with adverse structural change and positive genetic status.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38385929/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38385929</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.006>10.1016/j.jacc.2024.01.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38385929</guid>
<pubDate>Thu, 22 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>George Joy</dc:creator>
<dc:creator>Luis R Lopes</dc:creator>
<dc:creator>Matthew Webber</dc:creator>
<dc:creator>Alessandra M Ardissino</dc:creator>
<dc:creator>James Wilson</dc:creator>
<dc:creator>Fiona Chan</dc:creator>
<dc:creator>Iain Pierce</dc:creator>
<dc:creator>Rebecca K Hughes</dc:creator>
<dc:creator>Konstantinos Moschonas</dc:creator>
<dc:creator>Hunain Shiwani</dc:creator>
<dc:creator>Robert Jamieson</dc:creator>
<dc:creator>Paula P Velazquez</dc:creator>
<dc:creator>Ramya Vijayakumar</dc:creator>
<dc:creator>Erica Dall'Armellina</dc:creator>
<dc:creator>Peter W Macfarlane</dc:creator>
<dc:creator>Charlotte Manisty</dc:creator>
<dc:creator>Peter Kellman</dc:creator>
<dc:creator>Rhodri H Davies</dc:creator>
<dc:creator>Maite Tome</dc:creator>
<dc:creator>Vladan Koncar</dc:creator>
<dc:creator>Xuyuan Tao</dc:creator>
<dc:creator>Christoph Guger</dc:creator>
<dc:creator>Yoram Rudy</dc:creator>
<dc:creator>Alun D Hughes</dc:creator>
<dc:creator>Pier D Lambiase</dc:creator>
<dc:creator>James C Moon</dc:creator>
<dc:creator>Michele Orini</dc:creator>
<dc:creator>Gabriella Captur</dc:creator>
<dc:date>2024-02-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Electrophysiological Characterization of Subclinical and Overt Hypertrophic Cardiomyopathy by Magnetic Resonance Imaging-Guided Electrocardiography</dc:title>
<dc:identifier>pmid:38385929</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.006</dc:identifier>
</item>
<item>
<title>Thromboxane biosynthesis and future events in diabetes: the ASCEND trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38385506/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The U-TXM was log-linearly independently associated with SVE-R in diabetes. This is consistent with the involvement of platelet TXA2 in diabetic atherothrombosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 22:ehad868. doi: 10.1093/eurheartj/ehad868. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Thromboxane (TX) A2, released by activated platelets, plays an important role in atherothrombosis. Urinary 11-dehydro-TXB2 (U-TXM), a stable metabolite reflecting the whole-body TXA2 biosynthesis, is reduced by ∼70% by daily low-dose aspirin. The U-TXM represents a non-invasive biomarker of in vivo platelet activation and is enhanced in patients with diabetes. This study assessed whether U-TXM is associated with the risk of future serious vascular events or revascularizations (SVE-R), major bleeding, or cancer in patients with diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The U-TXM was measured pre-randomization to aspirin or placebo in 5948 people with type 1 or 2 diabetes and no cardiovascular disease, in the ASCEND trial. Associations between log U-TXM and SVE-R (n = 618), major bleed (n = 206), and cancer (n = 700) during 6.6 years of follow-up were investigated by Cox regression; comparisons of these associations with the effects of randomization to aspirin were made.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Higher U-TXM was associated with older age, female sex, current smoking, type 2 diabetes, higher body size, urinary albumin/creatinine ratio of ≥3 mg/mmol, and higher estimated glomerular filtration rate. After adjustment for these, U-TXM was marginally statistically significantly associated with SVE-R and major bleed but not cancer [hazard ratios per 1 SD higher log U-TXM (95% confidence interval): 1.09 (1.00-1.18), 1.16 (1.01-1.34), and 1.06 (0.98-1.14)]. The hazard ratio was similar to that implied by the clinical effects of randomization to aspirin for SVE-R but not for major bleed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The U-TXM was log-linearly independently associated with SVE-R in diabetes. This is consistent with the involvement of platelet TXA2 in diabetic atherothrombosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38385506/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38385506</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad868>10.1093/eurheartj/ehad868</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38385506</guid>
<pubDate>Thu, 22 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Giovanna Petrucci</dc:creator>
<dc:creator>Georgina A Buck</dc:creator>
<dc:creator>Bianca Rocca</dc:creator>
<dc:creator>Sarah Parish</dc:creator>
<dc:creator>Colin Baigent</dc:creator>
<dc:creator>Duaa Hatem</dc:creator>
<dc:creator>Marion Mafham</dc:creator>
<dc:creator>Aida Habib</dc:creator>
<dc:creator>Louise Bowman</dc:creator>
<dc:creator>Jane Armitage</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-02-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Thromboxane biosynthesis and future events in diabetes: the ASCEND trial</dc:title>
<dc:identifier>pmid:38385506</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad868</dc:identifier>
</item>
<item>
<title>Neurodevelopmental Outcomes for Individuals With Congenital Heart Disease: Updates in Neuroprotection, Risk-Stratification, Evaluation, and Management: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38385268/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>Over the past decade, new research has advanced scientific knowledge of neurodevelopmental trajectories, factors that increase neurodevelopmental risk, and neuroprotective strategies for individuals with congenital heart disease. In addition, best practices for evaluation and management of developmental delays and disorders in this high-risk patient population have been formulated based on literature review and expert consensus. This American Heart Association scientific statement serves as an...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 22. doi: 10.1161/CIR.0000000000001211. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Over the past decade, new research has advanced scientific knowledge of neurodevelopmental trajectories, factors that increase neurodevelopmental risk, and neuroprotective strategies for individuals with congenital heart disease. In addition, best practices for evaluation and management of developmental delays and disorders in this high-risk patient population have been formulated based on literature review and expert consensus. This American Heart Association scientific statement serves as an update to the 2012 statement on the evaluation and management of neurodevelopmental outcomes in children with congenital heart disease. It includes revised risk categories for developmental delay or disorder and an updated list of factors that increase neurodevelopmental risk in individuals with congenital heart disease according to current evidence, including genetic predisposition, fetal and perinatal factors, surgical and perioperative factors, socioeconomic disadvantage, and parental psychological distress. It also includes an updated algorithm for referral, evaluation, and management of individuals at high risk. Risk stratification of individuals with congenital heart disease with the updated categories and risk factors will identify a large and growing population of survivors at high risk for developmental delay or disorder and associated impacts across the life span. Critical next steps must include efforts to prevent and mitigate developmental delays and disorders. The goal of this scientific statement is to inform health care professionals caring for patients with congenital heart disease and other key stakeholders about the current state of knowledge of neurodevelopmental outcomes for individuals with congenital heart disease and best practices for neuroprotection, risk stratification, evaluation, and management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38385268/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38385268</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001211>10.1161/CIR.0000000000001211</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38385268</guid>
<pubDate>Thu, 22 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Erica Sood</dc:creator>
<dc:creator>Jane W Newburger</dc:creator>
<dc:creator>Julia S Anixt</dc:creator>
<dc:creator>Adam R Cassidy</dc:creator>
<dc:creator>Jamie L Jackson</dc:creator>
<dc:creator>Richard A Jonas</dc:creator>
<dc:creator>Amy J Lisanti</dc:creator>
<dc:creator>Keila N Lopez</dc:creator>
<dc:creator>Shabnam Peyvandi</dc:creator>
<dc:creator>Bradley S Marino</dc:creator>
<dc:creator>American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young and the Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-02-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Neurodevelopmental Outcomes for Individuals With Congenital Heart Disease: Updates in Neuroprotection, Risk-Stratification, Evaluation, and Management: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38385268</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001211</dc:identifier>
</item>
<item>
<title>Professional Liability: The Problem That Will Not Go Away</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383102/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):869-872. doi: 10.1016/j.jacc.2024.01.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383102/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38383102</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.008>10.1016/j.jacc.2024.01.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383102</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Richard A Chazal</dc:creator>
<dc:creator>Fred M Kusumoto</dc:creator>
<dc:creator>B Hadley Wilson</dc:creator>
<dc:creator>Richard E Anderson</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Professional Liability: The Problem That Will Not Go Away</dc:title>
<dc:identifier>pmid:38383102</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.008</dc:identifier>
</item>
<item>
<title>Sports Participation by Athletes With Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38383101/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240227050924&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 27;83(8):865-868. doi: 10.1016/j.jacc.2023.12.021.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38383101/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240227050924&v=2.18.0.post9+e462414">38383101</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.021>10.1016/j.jacc.2023.12.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38383101</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>George J Annas</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Kimberly G Harmon</dc:creator>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Margot Putukian</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sports Participation by Athletes With Cardiovascular Disease</dc:title>
<dc:identifier>pmid:38383101</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.021</dc:identifier>
</item>





























</channel>
</rss>